rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Simeon George

Director

Company insider

Files Form 4 as: Director, CRISPR Therapeutics AG; Director and 10% owner, Andrx Corp /de/; Director, Nkarta; Director and 10% owner, Design Therapeutics; 10% owner, Odyssey Therapeutics; 10% owner, Avalyn Pharma; Director, Turning Point Therapeutics; Director and 10% owner, Principia Biopharma.

Every Form 4 they filed

In numbers

Trades disclosed
170
Buys
17
Sells
2
Bought
$214.6M
Sold
$752K
Companies
9
Companies where not an officer
9
First trade
10 Feb 2014
Last trade
14 Oct 2026
Last filed
16 Oct 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
CRSP CRISPR Therapeutics AGDirector · Genomics & Gene Editing · last 14 Oct 20262 buys · 1 sell
Andrx Corp /de/Director, 10% owner · last 28 Sep 20261 buy · 0 sells
NKTX NkartaDirector · Biotechnology · last 10 Jun 20262 buys · 0 sells
DSGN Design TherapeuticsDirector, 10% owner · Biotechnology · last 9 Jun 20264 buys · 0 sells
ODTX Odyssey Therapeutics10% owner · Biotechnology · last 11 May 20261 buy · 1 sell
AVLN Avalyn Pharma10% owner · Biotechnology · last 1 May 20261 buy · 0 sells
Turning Point TherapeuticsDirector · last 17 Aug 20223 buys · 0 sells
Principia BiopharmaDirector, 10% owner · last 28 Sep 20202 buys · 0 sells
Genocea BiosciencesDirector · last 10 Feb 20141 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
14 Oct 2026filed 16 Oct 2026CRSP CRISPR Therapeutics AGGenomics & Gene EditingSEC FORM 4 Code M$420K30,000 at $14.00filing
14 Oct 2026filed 16 Oct 2026CRSP CRISPR Therapeutics AGGenomics & Gene EditingSEC FORM 4 Sold$720K14,514 at $49.63filing
14 Oct 2026filed 16 Oct 2026CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene EditingSEC FORM 4 Code M—30,000 at $0.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—3,334,938filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—3,907,547 at $0.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—1,304,883 at $0.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—600,962 at $0.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—1,802,885 at $0.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—1,953,773 at $0.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—198,019 at $0.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—1,113,666filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—512,897filing
28 Sep 2026filed 29 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—3,907,547 at $0.00filing
28 Sep 2026filed 29 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—1,304,883 at $0.00filing
28 Sep 2026filed 29 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—600,962 at $0.00filing
28 Sep 2026filed 29 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—1,802,885 at $0.00filing
28 Sep 2026filed 29 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—1,953,773 at $0.00filing
28 Sep 2026filed 29 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—198,019 at $0.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/SEC FORM 4 Bought$10.1M592,593 at $17.00filing
28 Sep 2026filed 29 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—1,538,691filing

News

AI China And Biotech Investing With SR Ones Simeon George MDlifescienceleader.com · 12 Oct 2026ADARx Pharmaceuticals (NASDAQ:ADRX) Director Simeon George Buys 1,600,000 Shares of Company Stockdailypolitical.com · 30 Sep 2026Odyssey Therapeutics Announces Encouraging Phase 2a Ulcerative Colitis ResultsODTX · rttnews.com · 20 Oct 2026CRISPR Therapeutics Announces Chief Financial Officer TransitionCRSP · manilatimes.net · 19 Oct 2026Where Will CRISPR Therapeutics Stock Be in 2030?CRSP · aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRSP · aol.com · 18 Oct 2026ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Sees Significant Growth in Short InterestADRX · dailypolitical.com · 15 Oct 2026

2 headlines in the last 90 days name Simeon George; 5 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.

Sectors

Health Care13
Not placed7

Buys in green, sells in red, by the company’s sector.

Related people

Samarth KulkarniChief Executive Officer · Chief Executive Officer at CRISPR Therapeutics AG, filing Form 4 there in the last year
James R. KasingerGeneral Counsel and Secretary · General Counsel and Secretary at CRISPR Therapeutics AG, filing Form 4 there in the last year
ORBIMED ADVISORS LLCDirector and 10% owner · Director and 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
Erez ChimovitsDirector · Director at ADARx Pharmaceuticals, filing Form 4 there in the last year
Carl L. GordonDirector and 10% owner · Director and 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
Ali BehbahaniDirector · Also traded CRSP in the last 90 days